Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 396,100 shares, a drop of 37.6% from the December 15th total of 634,600 shares. Based on an average daily trading volume, of 9,330,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 4.8% of the company’s stock are short sold.

Institutional Investors Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC boosted its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 218,000 shares of the company’s stock after buying an additional 120,132 shares during the period. Armistice Capital LLC owned 10.39% of Genprex worth $411,000 as of its most recent SEC filing. Institutional investors own 14.05% of the company’s stock.

Genprex Trading Up 0.0 %

Shares of GNPX opened at $0.70 on Thursday. The stock has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.13. Genprex has a 1 year low of $0.28 and a 1 year high of $13.00.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.